0001865257-26-000003.txt : 20260303 0001865257-26-000003.hdr.sgml : 20260303 20260303095507 ACCESSION NUMBER: 0001865257-26-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260303 DATE AS OF CHANGE: 20260303 EFFECTIVENESS DATE: 20260303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allyx Therapeutics, Inc. CENTRAL INDEX KEY: 0001865257 ORGANIZATION NAME: EIN: 832648948 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-575214 FILM NUMBER: 26711423 BUSINESS ADDRESS: STREET 1: 470 JAMES STREET STREET 2: SUITE 007 CITY: NEW HAVEN STATE: CT ZIP: 06513 BUSINESS PHONE: 2038550400 MAIL ADDRESS: STREET 1: 470 JAMES STREET STREET 2: SUITE 007 CITY: NEW HAVEN STATE: CT ZIP: 06513 D 1 primary_doc.xml X0708 D LIVE 0001865257 Allyx Therapeutics, Inc. 555 Long Wharf Drive Floor 11 NEW HAVEN CT CONNECTICUT 06511 (908) 432-2845 DELAWARE None None Corporation true Stephen Bloch c/o Allyx, 555 Long Wharf Drive Floor 11 New Haven CT CONNECTICUT 06511 Executive Officer Director Stephen Strittmatter c/o Allyx, 555 Long Wharf Drive Floor 11 New Haven CT CONNECTICUT 06511 Director Paul Fonteyne c/o Allyx, 555 Long Wharf Drive Floor 11 New Haven CT CONNECTICUT 06511 Director Gregory P Ho c/o SMC, 650 Madison Avenue 20th Floor New York NY NEW YORK 10022 Director Robert A Bettigole c/o ESV, 33 Whitney Avenue New Haven CT CONNECTICUT 06510 Director Timothy Siegert c/o Allyx, 555 Long Wharf Drive Floor 11 New Haven CT CONNECTICUT 06511 Executive Officer Jennifer Gabler c/o Allyx, 555 Long Wharf Drive Floor 11 New Haven CT CONNECTICUT 06511 Executive Officer Biotechnology Decline to Disclose 06b false 2026-02-23 false true true Simple Agreements for Future Equity (SAFEs) false 0 4000000 3324918 675082 false 12 0 0 0 No amount other than ordinary course employment compensation is being paid to officers and directors. false Allyx Therapeutics, Inc. Dr. Stephen Bloch Dr. Stephen Bloch Chief Executive Officer 2026-03-03